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ABSTRACT: Although the majority of FDA and EMA approved therapeutic monoclonal antibodies (mAbs) are IgG1, the 
number of IgG4-based formats reaching the market is increasing. IgG4 differ from other mAb isotypes by its specificity to 
form half mAbs that recombine into bispecific (bsAbs) molecules, through a process termed fab-arm exchange (FAE). We 
report here the complementarity of native mass spectrometry (MS), ion mobility (IM) and collision induced unfolding (CIU) 
experiments for the structural characterization of member IgG4 subfamily (wild-type (wt), hinge-stabilized (hs, S228P mu-
tation) and the resulting bsAb IgG4s)). Native MS allows confirming/invalidating the occurrence of FAE as a function of 
these different types of IgG4. While IM-MS was unable to distinguish iso-cross-section IgG4 species, CIU experiments pro-
vide unique specific structural signatures of each individual IgG4 based on their specific unfolding pathways. Common CIU 
features of IgG4 formats include the observation of three conformational states and two transitions. In addition, CIU ex-
periments S228P mutation stabilized gas phase conformations of hsIgG4, in agreement with increased stability related to 
more rigid hinge regions. CIU patterns also appear to be more informative than IM-MS for bsAb structural characterization, 
unfolding signature of the bsAb being intermediate to the ones of the former parent wtIgG4s, highlighting that bsAb CIU 
profiles keep the memory of their origins. Altogether, our results demonstrate that CIU patterns can serve as mAb specific 
structural signatures and are mature to be included in MS-based analytical workflows for conformational/structural char-
acterization of mAb formats in early development phases and for multiple attribute monitoring. 
   Introduction 
Monoclonal antibody-based therapeutics (mAbs) are the 
most promising drug class for clinical treatment of cancers, 
autoimmune diseases, cardiovascular disorders, 
ophthalmic diseases or asthma1-3. More than 70 mAbs and 
related products have been approved by the Food and Drug 
Administration (FDA) and by the European Medicine 
Agency (EMA)4, with more than 500 currently in clinical 
development1, 5. Since the mid-1990s, different strategies 
have been developed in order to produce more efficient 
and specific antibody-based therapeutics, giving rise to a 
plethora of mAbs and related products, such as antibody 
drug conjugates (ADCs)6, Fab fragments, 
radioimmunoconjugates7, and bispecific antibodies 
(bsAb)8.  
Most currently approved mAbs are selected from three 
human IgG isotypes (1, 2 or 4), which are defined by 
different heavy-chain amino acid sequences9, the total 
number of disulfide bridges (16 for IgG1 and IgG4 and 18 for 
IgG2) and disulfide bond connectivities between heavy 
chains in the flexible hinge region (two for IgG1 and IgG4, 
four for IgG2). Currently, the majority of mAbs and ADCs 
approved by the FDA and the EMA are based on the IgG1 
isotype (chimeric, humanized or human)10, while IgG3 is 
not used in the form of therapeutics owing to a 
significantly faster clearance rate (up to three times faster). 
IgG1 is considered to be easier to develop than IgG2 (more 
complex hinge region)11 or wt-IgG4. Human IgGs of 
different isotypes also differ in their ability to support 
secondary immune functions: IgG1 can usually support 
antibody-dependent cellular cytotoxicity (ADCC) and 
complement-dependent cytotoxicity (CDC), whereas IgG2 
and IgG4 are typically inefficient or limited in their effector 
functions12. Human IgG4 may sometimes support 
antibody-dependent cellular phagocytosis (ADCP)13. The 
number of IgG4-based therapeutics reaching the market 
and in clinical trials is increasing progressively14, serving as 
the basis for a variety of mAb formats including ADCs10, 
naked mAbs, PEGylated Fabs15, Fc-fusion peptides16 and 
bsAbs17 (see Supporting Information Table S1). The interest 
in IgG4 mAbs in the biopharmaceutical field stems from its 
ability to form half mAbs (one heavy and one light chain; 
75 kDa)18 and bsAbs in vitro and in vivo (through a process 
termed Fab-arm exchange (FAE) when not stabilized by a 
serine-to-proline mutation in the hinge region19. BsAbs are 
thus able to bind to two different types of antigens20. 
Natalizumab, indicated for multiple sclerosis, and more 
 recently reslizumab, intended for severe asthma, are 
examples of so-called wild-type (wt) therapeutic IgG4s. 
This particular characteristic of IgG4 mAbs can be 
explained by different determinants in the primary 
structure compared to other IgGs; namely, the flexibility 
associated with the IgG4 hinge region (shorter than IgG1), 
the relatively labile disulfide bonds between the two heavy 
chains in the hinge region, and the non-covalent 
interactions between the two CH3 domains of the two 
heavy chains facilitate the H-L pair exchange between two 
IgG4s (Figure 1)19. As pharmacokinetics and 
pharmacodynamics of wt-IgG4 mAbs can vary as a 
function of FAE and lead to undesired clinical effects, 
biopharmaceutical companies have made remarkable 
progress in developing more stabilized IgG4 formats, by 
introducing S228P point mutation in the core-hinge 
sequence of IgG4 mAbs that avoids FAE21. Currently, most 
of the biopharmaceutical companies are using such hinge 
stabilized IgG4 versions in order to abrogate FAE and 
address regulatory authority safety concerns22. 
Pembrolizumab23 and nivolumab24 are two examples of 
such hinge-stabilized engineered IgG4 formats that have 
been approved for cancer treatment25. 
 
Figure 1. a) Schematic representation of FAE reaction 
between two wt-IgG4s. b) Difference between the core-
hinge region of wt-IgG4 (left) and hs-IgG4 mAbs (right). 
 
Using native mass spectrometry, which has been 
demonstrated to be mature enough to be integrated into 
routine analytical workflows for mAb homogeneity 
assessment and the critical quality attribute determination 
of mAbs26-29, we aimed to promote the use of native ion 
mobility mass spectrometry (IM-MS) along with gas-phase 
collision-induced unfolding (CIU) for their structural 
characterization. CIU approaches have been reported to 
circumvent poor IM separation of co-migrating species 
that exhibit very close structures30-31. In particular, Tian et 
al.32 demonstrated that CIU experiments allow for 
distinguishing the four different mAb IgG isotypes, 
showing that IM migration times and the unfolding 
transitions strongly depend on the number of disulfide 
bond patterns within the isotype structures of the mAbs.  
In the present work, we focus on the combination of ad-
vanced native MS and IM-MS approaches for the structural 
characterization of different therapeutic IgG4 formats; 
namely, two wt-IgG4s (natalizumab and reslizumab), two 
hinge stabilized (hs) hs-IgG4s (pembrolizumab and 
nivolumab) and the bsAb formed after FAE between wt-
IgG4s. Native MS allows for confirming/infirming the oc-
currence of FAE and subsequent bsAb formation as a func-
tion of the IgG4 format (wt versus hs). The global charac-
terization of wt-IgG4 and hs-IgG4s and TWCCSN2 measure-
ments were performed by IM-MS, along with experiments 
involving CIU, as the specific signature of individual ther-
apeutic protein, revealing that hs-IgG4 constructs are less 
prone to unfolding than wt-IgG4, in agreement with in-
creased gas-phase stability related to hinge region rigidity. 
The CIU signature of FAE-produced bsAb also clearly 
demonstrate that its gas-phase stability is intermediate be-
tween parent IgG4s. Altogether, our results demonstrate 
that CIU experiments are unique fingerprints of biologics.  
  
Materials and methods 
FAE reaction natalizumab/reslizumab bsAb formation. 
Different mixtures of two IgG4 mAbs were used to form 
bsAb. Either two wt-IgG4 mAbs (natalizumab and 
reslizumab), or one wt-IgG4 (natalizumab) and one hs-
IgG4 (nivolumab), or two hs-IgG4s (pembrolizumab and 
nivolumab) were used to produce bsAb through FAE 
reaction. Endogenous half-molecule swapping conditions 
were mimicked by using glutathione (GSH, Sigma) as a 
reducing agent. Initially, parental mAbs were diluted in 
200 µl of 1xPBS solution, leading to a final concentration of 
1 mg/ml for each individual antibody. The three different 
equimolar mixtures of parental mAbs were subsequently 
incubated for 24 h in the presence of 0.5 mM of GSH. 
Native MS experiments 
Natalizumab (Tysabri, Biogen), reslizumab (Cinqaero, 
Teva), nivolumab (Opdivo, BMS) and pembrolizumab 
(Keytruda, MSD) were obtained from their respective 
manufacturers. Primary sequences of wt- and hs-IgG4s 
along with expected masses are provided as Supplementary 
Information Figure S1. Each individual mAb and all the 
equimolar mixtures of two IgG4s were N-deglycosylated 
for 30 min at 37 °C with IgGZERO (Genovis) and 
subsequently desalted against 100 mM of ammonium 
acetate at pH 7 prior to native MS analysis, using eight 
cycles of a centrifugal concentrator (Vivaspin, 30 kDa 
cutoff, Sartorious, Göttingen, Germany). 
The concentration of each individual solution after the 
desalting process was assessed by UV absorbance using a 
nanodrop spectrophotometer (Thermo Fisher Scientific, 
France). Prior to native MS analysis, all the samples were 
diluted in 100 mM of ammonium acetate at pH 7 to a final 
concentration of 5 µM. For IdeS (immunoglobulin-
degrading enzyme of Streptococcus pyogenes) enzymatic 
treatment, one hundred units of IdeS enzyme 
(FabRICATOR, Genovis) were added to 100 µg of mAbs in 
50 mM Na2HPO4 and 150 mM NaCl at pH 6.6, and the 
mixture was incubated at 37 °C for 60 minutes. The Ides-
digested IgG4 formats were also desalted against 100 mM 
of ammonium acetate and subsequently diluted to reach a 
final concentration of 5 µM. 
 Native mass spectra were recorded either on an Orbitrap 
Exactive Plus EMR (Thermo Fisher Scientific, Bremen, 
Germany) or a QTOF (Synapt G2 HDMS, Waters, 
Manchester, U.K.) mass spectrometer, both coupled to an 
automated chip-based nanoelectrospray device (Triversa 
Nanomate, Advion, Ithaca, USA) operating in the positive 
ion mode. The capillary voltage and the pressure of the 
nebulizer gas on the Orbitrap Exactive Plus EMR were set 
at 1.8-1.9 kV and 0.15 psi, respectively. Ions were driven 
through the mass spectrometer with an in-source voltage 
of 150 eV and then thermalized in the HCD cell at 50 eV. 
The constant N2 pressure in the backing source region, the 
HCD cell and the orbitrap analyzer were set to 2, 10-5 and 
10-9 mbar, respectively. Native MS data treatment was 
performed with the BioPharmaFinder 3.0 (Thermo Fisher 
Scientific, Bremen, Germany). Q-TOF parameters were 
optimized as previously described in Debaene et al 33. 
Briefly, the cone voltage of the source interface was set to 
120 V and the backing pressure was increased to 6 mbar to 
optimize the transmission of the molecular ions. Mass 
spectra recorded with Synapt G2 platform were analyzed 
with MassLynx 4.1 (Waters, Manchester, U.K.).   
Native IM-MS and CIU experiments 
Ion mobility experiments were performed on a hybrid 
QTOF mass spectrometer (Synapt G2, Waters, 
Manchester, UK). The mass spectrometer was carefully 
parametrized in order to avoid ion activation. The backing 
pressure was set to 6 mbar and the cone voltage to 80 V in 
order to improve the transmission of “native-like” ions. 
The travelling wave-based ion trap was filled with a 
continuous Ar flow of 120 mL/min and the trap collision 
energy was set to 4 V. Ions were separated in the TWIMS 
cell using a constant N2 pressure of 2.4 mbar. The IM wave 
velocity and height were set to 800 m/s and 40 V, 
respectively. IM data were calibrated as described 
elsewhere34. Briefly, three charge state of three external 
calibrants (concanavalineA, alcohol dehydrogenase and 
pyruvate kinase) were used to determine the collision cross 
section of the ion of interest. MassLynx 4.1 was used to 
perform IM data interpretation. Reported TWCCSN2 values 
correspond to the average TWCCSN2 measurement 
performed in triplicate under the same experimental 
conditions.  
For the CIU experiments, ions were progressively 
activated in the trap cell by increasing the trap collision 
voltage in 5-V steps from 0 to 200 V prior to IM separation 
during 1-minute run. Ion mobility data, specific to each 
individual charge state, were compiled to give rise to the 
CIU fingerprints. CIU data, were analyzed with the open-
source CIU_Suite software35, allowing the arrival time 
distribution (ATD) extraction of specific ions at each trap 
collision voltage. The ATDs were smoothed using a 
Savitzky-Golay algorithm with a window length of 3 and a 
polynomial order of 2. CIU experiments have been 
performed in triplicate for each individual mAbs leading to 
a standard deviation lower than 4%, calculated from the 
CIUSuite_Stat module of CIU_Suite open-source software.  
    
Results and discussion 
Native mass spectrometry of wild-type and hinge-
modified IgG4 formats 
We first used native MS to check the FAE capabilities of 
our therapeutic mAbs. Figure 2 presents the FAE 
experiments involving different combinations of wt- and 
hs-IgG4 mAbs after 24 hours of incubation in the presence 
of GSH (Materials and methods). As expected, the hybrid 
bsAb was only formed when two wt-IgG4 mAbs were 
combined. Three species including the former mAbs 
(natalizumab and reslizumab, 146621 ± 1 Da and 144260 ± 5 
Da, respectively) and the additional formation of the bsAb 
(145441 Da ± 4 Da) were detected (Figure 2a). At lower m/z, 
small amounts of natalizumab and reslizumab half mAbs 
were also observed (<5%), pinpointing that our 
experimental conditions were carefully adapted to 
minimize wt-IgG4 dissociation (see Supporting 
Information Figure S2). The relative intensity of 
natalizumab, reslizumab and the newly formed bsAb 
revealed that FAE reaction reached equilibrium after a 24-
h reaction, which is in good agreement with previous 
results obtained by Debaene et al33. Conversely, only two 
species corresponding to the parent mAbs were detected 
in the case of equimolar mixtures of either one wt- and one 
hs-IgG4 (Figure 2b) or two hs-IgG4s (Figure 2c), as 
previously reported22, 36-37. 
 
 
Figure 2. Native mass spectrometry to monitor FAE. 
Native mass spectra of (a) natalizumab/reslizumab wt-/wt-
IgG4s, (b) natalizumab/nivolumab wt-/hs-IgG4s and (c) 
pembrolizumab/nivolumab hs-/hs-IgG4s mixtures 
obtained after 24-h incubation in the presence of GSH. Left 
panels represent the full-scan native mass spectra and a 
zoom on the 24+ charge state as inset; the right panel 
presents the corresponding deconvoluted mass spectra. 
 
Native IM-MS for the global characterization of 
IgG4 formats 
The global conformation of each individual IgG4 was 
next characterized using native IM-MS. Despite fine-
tuning of IM-MS parameters (see Materials and methods) 
to provide the best separation of all the species without ion 
activation, all IgG4s formats (wt and hs) show very similar 
 IM drift times and subsequent TWCCSN2 (Figure 3). Very 
similar ATDs can be observed between wt-IgG4s 
(natalizumab, reslizumab) and hs-IgG4s (pembrolizumab, 
nivolumab), as depicted on the 22+ charge state in Figure 
3b. For wt-IgG4s, slight TWCCSN2 differences (∼0.5 nm2) are 
observed between natalizumab and reslizumab, which 
could be attributed to a mass effect, with natalizumab 
presenting a mass increase of 2 kDa compared to 
reslizumab (expected CCS increase for 2 kDa is 0.7 nm2)38. 
The same reasons account for the TWCCSN2 differences 
observed between pembrolizumab and nivolumab hs-
IgG4s. The inability of IM-MS to distinguish very close 
conformations was even more pronounced for higher 
charge state (Figure 3a). This effect is more likely due to 
the columbic repulsion as a consequence of the number of 
protons harbored within the structure of the IgG4 mAbs39. 
As the studied IgG4 mAbs share a sequence identity of 
more than 90% (Supporting Information table S2), possess 
similar domain structures, all have masses of ∼145 kDa and 
display the same number of disulfide bridges in the hinge 
region (Figure 1), it was expected to be challenging to 
distinguish these IgG4 formats based on the sole use of IM-
MS data due to the current inadaptability between too low 
resolutive ion mobility cells and resolving power that 
would be necessary to detect such subtle conformational 
changes (theoretical IM resolving powers Ω/∆Ω > 700 at 
FWHM would be required to distinguish TWCCSN2 
differences of 0.1 nm2 on intact mAbs). Altogether, these 
results highlight the difficulty in detecting the subtle 
conformational variations at the intact mAb level only by 
IM-MS on IgG4 formats that have different hinge amino 
acid sequences with strong impact on biological 
activities (occurrence of FAE or not for wt-IgG4 and hs-
IgG4s, respectively). 
 
 
Figure 3. Native IM-MS for conformational 
characterization of IgG4 formats. (a) TWCCSN2 
measurements as a function of the charge state. (b) ATDs 
of the 22+ charge state of the four IgG4 formats and 
comparison with the theoretical TWCCSN2 values calculated 
from CCS=2.435*(M)(2/3) (dashed lines)38.(c) Table 
summarizing all the TWCCSN2 measurements with the 
standard deviation for each individual charge state. 
 
Collision-induced unfolding to monitor IgG4 hinge 
stabilization 
We next performed CIU experiments, a methodology 
that has been reported to be able to detect subtle 
conformational changes31, 40, on therapeutic wt- 
(natalizumab and reslizumab) and hs- (pembrolizumab 
and nivolumab) IgG4. All four mAbs were subjected to gas-
phase ion activation by increasing the trapping voltage 
progressively (see Materials and methods). Figure 4 depicts 
the CIU fingerprints of the 22+ charge state of the different 
IgG4s. This charge state was chosen to record the CIU 
fingerprint taking into account that high charge state can 
lead to numerous CIU transitions. Three main CIU features 
are observed for wt-IgG4 (Figure 4a and b): the initial 
compact state (state 0) and two additional unfolded states 
(state 1 and 2, respectively), in agreement with results 
reported by Ruotolo’s groups on a commercial IgG432. For 
both natalizumab and reslizumab, initial compact states 
have similar lengths and very close centroid IM drift times 
(16.1 and 15.6 ms, respectively). The first transition from the 
initial compact state (state 0) to the first intermediate state 
(state 1) occurs between 35 and 40 V. However, clear CIU 
differences are observed between both wt-IgG4s at higher 
collision voltages (Figure 4c). The intermediate unfolding 
state (state 1) of natalizumab is observed over a wide range 
of collision voltages (45-200 V), being the most intense 
conformer from 50 to 140 V. However, state 1 of reslizumab 
is only the most intense conformer between 45 and 120 V, 
pinpointing that the latter’s intermediate unfolding state 1 
undergoes isomerization faster than state 1 of natalizumab. 
Furthermore, state 2 of natalizumab becomes the most 
intense structure at 140 V, whereas state 2 of reslizumab 
can be observed as the most important isomer when the 
acceleration voltage is set to 125 V. According to our 
results, the 22+ charge state of reslizumab is more prone to 
unfolding due to the fact that the two observed transitions 
occur at lower accelerating voltages. This behavior is also 
observed in the CIU fingerprints corresponding to higher 
charge state (see Supporting Information Figure S3). The 
reason for differences in reslizumab and natalizumab gas-
phase sensitivity (both IgG4s bearing the same number 
and network of disulfide bonds in the hinge region), may 
be explained by differences in primary sequences of mAbs. 
To get more details about the mechanism of gas-phase 
unfolding, we next performed CIU experiments on 
individual F(ab’)2 and Fc fragments (see Supporting 
Information Figure S4 and S5) of both wt-IgG4s generated 
after IdeS enzymatic treatment (see Materials and 
methods). IdeS cleaves IgGs between the Fc and F(ab’)2 at 
a single site at the lower hinge region leaving both 
fragments intact41, generating two domains named F(ab’)2 
and Fc. Almost no differences in CIU patterns could be 
observed for Fc fragments (see Supporting Information 
Figure S5), in agreement with the high sequence homology 
(see Supporting Information Table S2) and conserved Fc 
domain structure for both wt-IgG4s. Conversely, CIU 
fingerprints originating from F(ab’)2 domains of 
reslizumab and natalizumab were significantly different. 
The same trend is observed for F(ab’)2 fragments than for 
 intact wt-IgG4s, namely that the lightest F(ab’)2 (96071 Da) 
of reslizumab is more prone to gas phase unfolding than 
natalizumab’s F(ab’)2 (98468 Da). As disulfide bridging is 
a critical quality attribute checked for batch release, we can 
assume that both mAbs have the same number of disulfide 
bridges but also the same connectivity in the hinge region. 
Therefore, these additional CIU experiments allow 
concluding that F(ab’)2 fragments are responsible of the 
unfolding process differences observed on intact wt-IgG4s.  
Altogether, our results clearly demonstrate that the 
unfolding mechanism of wt-IgG4 mAbs is driven by F(ab’)2 
domains. As wt-IgG4s share the same number of disulfide 
bridges in the hinge region and also have the same inter 
heavy-chain/light chain, differences in primary sequences 
of F(ab’)2 domains (including variable domains) might 
account for the specific gas phase unfolding of each wt-
IgG4. In addition, we highlight that CIU patterns can act as 
specific fingerprints/signatures of each individual 
biotherapeutic. 
CIU fingerprints of hs-IgG4 pembrolizumab and 
nivolumab were very similar to those of wt-IgG4s (Figure 
4). Three main CIU features were observed: the initial com-
pact state 0 and two unfolding states (state 1 and state 2). 
The centroid IM drift times of both pembrolizumab and 
nivolumab state 0 were 16.0 and 15.5 ms, respectively. The 
collision energy characteristic of two unfolding transitions 
and the IM drift times are rather similar for both hs-IgG4 
formats. Thus, the first transition can be observed at 45 V 
(state 0 to state 1), with both pembrolizumab and 
nivolumab undergoing complete unfolding into state 2 be-
tween 75 and 200 V. Conversely to wt-IgG4s, a detailed 
comparison of both CIU fingerprints does not reveal any 
significant conformational difference (Figure 4f). Similarly 
to wt-IgG4s, Fc fragments of hs-IgG4s obtained after IdeS 
digestion were not significantly different while F(ab’)2 
fragments allow distinguishing the two hs-IgG4s, high-
lighting again that CIU pattern of F(ab’)2 fragment act as 
signature of each mAb (see Supporting Information Figure 
S5). 
  
Figure 4. CIU fingerprints of the 22+ charge state of 
natalizumab (a), reslizumab (b), pembrolizumab (d), 
nivolumab (e), and differential CIU maps between 
reslizumab (red) and natalizumab (blue) (c), 
pembrolizumab (red) versus nivolumab (blue) (f), 
natalizumab (blue) vs pembrolizumab (red) (g), and 
reslizumab (blue) vs nivolumab (red) (h) from 0 to 200 V 
trap voltage. 
 
Finally, we compared CIU patterns of wt- and hs-IgG4s, 
both containing four interchain disulfide bonds, but 
different hinge amino acid sequences and additional 
“flexibility/dynamics” in the hinge region of hs-IgG4 
(Figure 1). An overall comparison of the CIU data acquired 
for these two IgG4 categories reveals many similarities. 
But, after detailed analysis, differences concerning the 
voltage associated with the unfolding transition can be 
distinguished. As previously observed in the wt-IgG4 
differentiation, no significant differences are observed in 
the low voltage region (between 0 and 70 V), as the initial 
compact state 0 of all mAbs has an IM drift time of between 
15.5 and 16.1 ms, with the first unfolding process also 
occurring between 35 and 40 V for the 22+ charge state of 
all mAbs (Figures 4 and 5). Most significant differences 
between wt- and hs-IgG4s can be observed in the high 
voltage region for the second conformational transition 
from unfolded state 1 to unfolded state 2 (Figure 5). At 140 
V, the relative intensity of the state 2 of the two wt-IgG4s 
is 49% and 58% for natalizumab and reslizumab, 
respectively, which is higher compared to the relative 
intensities of the state 2 for hs-IgG4s (42% for both 
pembrolizumab and nivolumab). These observations 
emphasize that the second unfolding transition is slower 
for hs-IgG4s than for wt- mAbs, in agreement with a better 
resistance to gas-phase unfolding for hs-IgG4 formats 
compared to wt ones. 
  
Figure 5. Extracted ATDs of 22+ charge state of wt- and 
hs-IgG4s at different collision energies (40 and 140 V). 
 
IM-MS and CIU experiments to compare bsAb to 
former parent wt-IgG4 mAbs 
We next focused on the IM-MS investigation of the bsAb 
formed between wt-IgG4s. Under our experimental 
conditions, IM-MS assays resulted in a TWCCSN2 
measurement of 69.9 nm2 for the 22+ charge state of 
natalizumab/reslizumab bsAb. Of note, the TWCCSN2 of 
bsAb corresponds to the average TWCCSN2 of natalizumab 
and reslizumab (70.1 and 69.6 nm2, respectively), which 
leads to the conclusion that no significant global structure 
modifications are induced through FAE reaction. 
Theoretical calculations, based on the empirical TWCCSN2 
equation for globular proteins, estimated an increase of 0.3 
nm2 for reslizumab TWCCSN2 after the addition of the HL 
pair of natalizumab, regardless of the charge state of the 
different species, which perfectly matches our 
experimental results (∆TWCCSN2 (natalizumab/reslizumab) 
= 0.3 ± 0.1 nm2).  
We next generated the CIU fingerprint of the newly 
formed bsAb in order to obtain more structural insights 
into the interaction between the two H-L pairs after FAE 
reaction (Figure 6a). As previously observed for all the IgG4 
formats, the CIU fingerprint exhibits two unfolding 
transitions and three different conformational states. The 
centroid IM drift time associated with the initial compact 
state of bsAb is 15.9 ms; after ion activation, the 
corresponding IM drift time of the most unfolded structure 
is 20.5 ms, leading to a relative TWCCSN2 increase of 6.3%. 
In spite of the overall similarity of the bsAb and the 
previous IgG4 fingerprints, the collision voltage of the 
unfolding transitions is not completely the same.  
The IM drift time of the most intense ATD distribution 
of natalizumab, reslizumab and the bsAb were monitored 
as a function of the collision voltage in order to compare 
the gas-phase unfolding of the three IgG4s involved in FAE 
reaction (Figure 6b and Supporting Information Figure 
S6). All along the trap voltage range (0-200 V), the IM drift 
time of the bsAb, and therefore its TWCCSN2, is significantly 
different and systematically in between the values of its 
two parental wt-IgG4s. Furthermore, the two bsAb 
unfolding transitions occur at 45 V (reslizumab 40 V and 
natalizumab 50 V) and 140 V (reslizumab 120 V and 
natalizumab 160 V), which means that both occur between 
the natalizumab and reslizumab unfolding transitions, 
highlighting that the global conformation and the gas-
phase unfolding of the newly formed bsAb are directly 
related to the structure and gas-phase stability of both 
parental mAbs. 
 
Figure 6. CIU of bsAb formed between natalizumab and 
reslizumab. (a) CIU fingerprint of the newly formed bsAb 
after FAE. (b) Evolution of the drift time of 22+ charge state 
of bsAb (blue), natalizumab (red), and reslizumab (black) 
as a function of the collision energy. 
 
Concluding remarks 
Here, we report on the complementarity of advanced 
CIU experiments with native MS and IM-MS in order to 
provide a global picture of the structure and gas-phase 
unfolding of IgG4-related mAb products. Native MS allows 
for the direct evaluation of the extent of FAE and the 
subsequent bsAb formation, which is a critical quality 
attribute requested by regulatory agencies in the approval 
of wt-IgG4 formats and as a negative control for FAE for 
hs-IgG4s. In addition, IM-MS approaches are foreseen to 
provide structural information on mAb structures. 
However, mAbs with identical or very closely related 
 structures could co-migrate in classical IM-MS 
experiments, due to the fact that current IM drift cells do 
not provide the necessary resolving power to distinguish 
between subtle structural differences. This is the case in 
our study for IgG4 mAbs with very similar primary 
sequences, as well as identical numbers and pairing of 
disulfide bonds, leading to very similar IM drift times and 
TWCCSN2 values. Finally, CIU experiments performed either 
at the intact or middle (after IdeS enzymatic digestion) 
level enable the in-depth characterization and detailed 
differentiation of IgG4 formats. Activation of molecular 
ions prior to IM separation (CIU) has been proven to be a 
sensitive technique to assess the gas-phase stability of 
protein conformers30, and particularly to differentiate the 
four IgGk subclasses32. We focused here on one of these 
mAb isotype families (IgG4) and took a closer look at the 
subtle differences that can exist within this family, by 
comparing CIU patterns of wt-, hs- and bsAb-IgG4s. 
Similar global CIU fingerprints were obtained for wt-, hs- 
and bsAb-IgG4 formats, highlighting three main 
conformational states and two transitions. However, a 
detailed analysis of these gas-phase CIU fingerprints 
revealed small differences in terms of collision energies at 
which the unfolding transitions occur (higher energies for 
hs-IgG4), along with differences in the width of the energy 
range of the intermediate conformational states (unfolding 
state 1 of hs-IgG4 is more intense throughout the collision 
energy range). CIU experiments performed at the middle 
level after IdeS treatment allow concluding that F(ab’)2 
domains drive the unfolding process of IgG4s. CIU was 
thus the only IM-MS based approach to unambiguously 
demonstrate the improved gas-phase stability of hs-IgG4, 
compared to other IgG4 formats, with hs-IgG4 mAbs (at 
both intact and middle level) being less prone to gas-phase 
unfolding, in agreement with less flexible hinge region 
scaffolds arising from the core-hinge S228P mutation. In 
the absence of three-dimensional structural data for most 
mAbs, CIU experiments appear to be an ingenious way to 
assess conformational rearrangements regarding small 
structural changes (protein isoforms30, chemical 
modifications31 etc.). Thus, CIU patterns can generate 
global isotypes fingerprints, as well as specific signatures of 
any individual mAb.    
The present study also focuses on the global 
conformational characterization of the bsAb formed upon 
FAE from two parent wt-IgG4s. Again, poor information 
can be deduced from the global structural IM-MS data, as 
similar TWCCSN2 are recorded for both wt-IgG4 parents and 
for the newly formed bsAb. Conversely, CIU patterns 
appear to be more informative as the unfolding signature 
of the bsAb is intermediate to the ones of the former parent 
wt-IgG4s throughout the collision energy range, 
highlighting that the bsAb formed upon FAE keeps the 
memory of its origins. As for wt- and hs-IgG4s, bsAb CIU 
fingerprints present three different conformational states 
for which transitions energies represent the mean of parent 
wt-IgG4 TWCCSN2.  
Altogether our work presents an exhaustive landscape of 
the possibilities of native MS, IM-MS and CIU for the 
conformational characterization of the subfamily of IgG4 
mAb formats. Native MS appears to be an alternative 
method to classical chromatographies42 used to monitor 
FAE, with the additional advantage of unambiguous mass 
identification of all detected species. Native MS, even when 
coupled to size exclusion chromatography for fast 
desalting26-27, 43, provides, within 5-min runs, valuable 
information for IgG4 homogeneity characterization, 
including the possibility to monitor dynamics of FAE 
processes. While IM-MS appears to be poorly informative 
for the structural characterization of members of the IgG4 
subfamily (wt-, hs- and bsAb-IgG4s), CIU experiments 
provide unique specific signatures of each individual IgG4, 
in turn providing resolution of these iso-cross-sectional 
species (which co-migrate in IM-MS) through their 
unfolding pathways. Common features of IgG4 formats 
include the observation of three conformational states and 
two transitions. Interestingly, CIU patterns of F(ab’)2 
fragments obtained after IdeS digestion also proved to be 
mAb-specific and can be seen as signatures/fingerprints of 
mAbs. In addition, CIU protocols are able to differentiate 
between stabilized and wt-IgG4s and can enable the 
assessment of mAb stabilities. We believe that CIU 
experiments can be included in MS-based analytical 
workflows for the conformational/structural 
characterization of mAb formats in early development 
phases and in multiple attribute monitoring workflows. 
ASSOCIATED CONTENT  
Supporting information  
Supporting Information Table S1, Table S2, Figure S1, Figure 
S2, Figure S3, Figure S4, Figure S5, and Figure S6 are available 
free of charge from the ACS Publications website. 
AUTHOR INFORMATION 
Corresponding author 
*Phone: +33 (0)3 68 85 26 79. Fax: +33 (0)3 68 85 27 81.  
E-mail: sarah.cianferani@unistra.fr 
Author contributions 
The manuscript was written with contributions from all 
authors. All authors have given approval to the final version 
of the manuscript. 
FUNDING SOURCES 
This work was supported by the CNRS, the Université de 
Strasbourg, the Agence Nationale de la Recherche and the 
French Proteomic Infrastructure (ANR-10-INBS-08-03).  
ACKNOWLEDGMENT  
The authors would like to thank GIS IBiSA and Région Alsace 
for financial support in purchasing a Synapt G2 HDMS 
instrument. O.A-H acknowledges the IdeX program of the 
University of Strasbourg for funding his postdoctoral 
fellowship. 
ABBREVIATIONS 
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IgG  immunoglobulin G 
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CIU  collision induced unfolding 
wt-  wild-type 
hs-  hinge-stabilized 
IMS  Ion mobility spectrometry 
MS  Mass spectrometry 
bsAb  bispecific antibody 
TWCCSN2 collision cross section measured in a 
TWIMS device with N2 as background 
gas 
ATD  Arrival time distribution 
F(ab’)2  Full fragment antigen-binding 
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